The global Guillain barre syndrome treatment market is anticipated to grow at a significant CAGR of 5.2% during the forecast period 2022-2028. As per the information provided by the United Nations, in 2020, there are an estimated 727 million persons aged 65 years or over across. Additionally, this number is projected to be more than double by 2050, reaching over 1.5 billion persons. So, the increasing elderly population, which leads to the pervasiveness of immunological illnesses is one of the primary factors driving the expansion of the guillain barre syndrome market.
Browse the full report of " Global Guillain Barre Syndrome Treatment Market Size, Share, and Trends Analysis Report By Type (Intravenous Immunoglobulin, Plasma Exchange, and Others) and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others) Forecast 2022-2028" at https://www.omrglobal.com/industry-reports/guillain-barre-syndrome-treatment-market
Further, the key players operating in the global guillain barre syndrome treatment market had been adopting strategies such as new launches and agreements to gain major market share. For instance, in November 2021, Biotest AG announced the authorization in France for the human intravenous immunoglobulin preparation that is Intratect which is manufactured and marketed by Biotest in two concentrations. The Intratect is an important component of Biotest's portfolio with over 50 approvals globally. The broad spectrum of indications includes substitution therapy for primary and secondary immunodeficiency diseases along with immunomodulation for primary immune thrombocytopenia, Guillain-Barré syndrome, and Kawasaki syndrome, among others. Further, in September 2019, Annexon Biosciences Inc., announced that the FDA had granted fast track designation to ANX005, a novel treatment for Guillain-Barré syndrome. ANX005 is a clinical-stage investigational monoclonal antibody intended to treat patients with autoimmune and neurodegenerative disorders and formulated for IV administration.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape - including, Bayer AG, Grifols SA, CSL Ltd., Octapharma AG, Kedrion Biopharma Inc., and Takeda Pharmaceutical Co. Ltd., among others.
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Guillain Barre Syndrome Treatment Market Report Segment
By Type
By Distribution Channel
Global Guillain Barre Syndrome Treatment Market Report Segment by Region
North America
Europe
Asia-Pacific